Starpharma tech ready to deliver
The Austraian published an interview with Starpharma CEO Dr Jackie Fairley where she discussed the potential of the dendrimer technology, how it is applied to cancer drugs and the potential benefits it provides to patients.
To read the full article, click here. (paywall)
Dendrimer drug delivery enhances chemotherapy gemcitabine in human pancreatic mode
Online pharmaceutical publication Pharma in Focus noted Starpharma’s positive DEP® gemcitabine results in a human pancreatic model, noting it was one of multiple DEP® drugs from the company.
To read the full article, click here.
DEP® gemcitabine outperforms Gemzar® in human pancreatic cancer model
Starpharma today announced results for its next internal development candidate, DEP® gemcitabine.
Quarterly Cashflow Report
Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 September 2019.
Starpharma’s cash balance as at 30 September 2019 was $36.8 million, with net operating cash outflows for the quarter of $4.6 million. The cash balance does not include the anticipated $4.9 million R&D tax incentive which is expected to be received during the December quarter.
Starpharma to present at US Drug Delivery Conference
Starpharma today announced that it has been invited once more to present at the 9th Annual Partnership Opportunities in Drug Delivery (PODD) conference in Boston, USA, on 7-8 October.
The PODD conference showcases the latest advances in drug delivery and provides networking opportunities with senior scientific and commercial executives from many of the major international pharmaceutical companies. This year’s PODD conference will be chaired by AstraZeneca’s Head of Drug Delivery, Dr Shawn Davis.
Small cap healthcare stocks surge to billion-dollar plays
The Australian Financial Review mentioned that Starpharma was in a group of small cap biotech stocks in stage two trials that investors are closely in the next few years.
To read the full article, click here (paywall)
FDA Authorisation of First-in-Human Clinical Trial with AstraZeneca’s DEP® product AZD0466
Starpharma today announced that that the U.S. Food and Drug Administration (FDA) has authorised the use of AstraZeneca’s DEP® Bcl2/xL conjugate AZD0466 in clinical trials under an investigational new drug (IND) application. This is the first DEP® candidate to reach this milestone from Starpharma’s multiproduct license with AstraZeneca.
DEP® irinotecan synergistic with Lynparza® in refractory human colon cancer model
Starpharma today announced that its patented clinical stage nanoparticle formulation, DEP® irinotecan, showed significantly enhanced efficacy benefits over standard irinotecan (Camptosar®) and olaparib (Lynparza®) alone and in combination, in an irinotecan-refractory HT-29 human colon cancer xenograft model.
Starpharma’s VivaGel® BV regulatory approvals continue in Asia
|
Finance News Network reported Starpharma received further regulatory approval in another Asian country for its breakthrough product for bacterial vaginosis, VivaGel® BV. The news follows the first approval in the region announced on 15 August. |
Read the full news coverage here.
VivaGel® BV regulatory approvals continue in Asia
Starpharma today announced that it has received a further regulatory approval in an Asian country for VivaGel® BV. This approval follows multiple country approvals in the region as previously announced on 15 August 2019. Mundipharma will be rolling-out the product in Asia under the brand name BETADINETM BV Gel.